DORMANT studio
localhost:3000

Opportunity radar

4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05

Showing50 of 77,862
Free-text
CPC starts with (comma sep)
Min fwd citations
Clear
Patent #TitleAssetsIssuedExpiresFwd citesScore
12616681Compositions and methods for treating renal injury🖼🧊📄§2026-05-052042-08-22031
12616677Injectable pharmaceutical compositions and uses thereof🖼🧊📄§2026-05-052040-05-01031
12616678Methods to of aldehyde dehydrogenases for treatment of cancer🖼🧊📄§2026-05-052041-06-10031
12616689Regimens of tafenoquine for prevention of malaria in malaria-naive subjects🖼🧊📄§2026-05-052043-08-30031
12616690Specific AKT3 activator and uses thereof🖼🧊📄§2026-05-052044-03-15031
12616687Treatment of viral infection, disease or disorder using a selective sir agonist🖼🧊📄§2026-05-052042-11-04031
12616694Pharmaceutical compositions for subcutaneous administration of levosimendan🖼🧊📄§2026-05-052041-12-08031
12616700Therapeutic regimen🖼🧊📄§2026-05-052043-07-07031
12616698Methods for reducing liver fat and for treating fatty liver disorders🖼🧊📄§2026-05-052043-11-22031
12616697Methods of treatment with myosin modulator🖼🧊📄§2026-05-052041-08-26031
12616708Methods for treating pulmonary non-tuberculous mycobacterial infections🖼🧊📄§2026-05-052044-11-07031
12616711Therapeutic dendrimer🖼🧊📄§2026-05-052040-09-25031
12616715Nanotherapy targeting RHAMM-positive tumors🖼🧊📄§2026-05-052041-04-23031
12616718Photosynthetic cellular substances and methods of use thereof🖼🧊📄§2026-05-052043-04-24031
12616722Treatment of immune disorders🖼🧊📄§2026-05-052045-01-17031
12616725Bifidobacterium breve IDCC 4401 strain and its dead cell ID-BBR4401 having excellent acid tolerance and bile tolerance and prophylactic or therapeutic effect on dyslipidemia🖼🧊📄§2026-05-052042-12-30031
12616724Pharmaceutical composition for preventing or treating intestinal damage comprising Leuconostoc citreum strain as active ingredient🖼🧊📄§2026-05-052042-02-07031
12616731Process for enhancing organoleptic properties of natural products and natraceuticals thereof🖼🧊📄§2026-05-052041-09-22031
12616728Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same🖼🧊📄§2026-05-052043-11-21031
12616732Peptides for treatment of medical disorders🖼🧊📄§2026-05-052042-07-11031
12616736Method of diagnosis of adrenal insufficiency🖼🧊📄§2026-05-052038-10-24031
12616735Compositions and methods of controlling expression of thermogenin (UCP-1) in skeletal muscles🖼🧊📄§2026-05-052039-07-03031
12616738Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid🖼🧊📄§2026-05-052042-11-16031
12616739GLP-1 prodrugs and uses thereof🖼🧊📄§2026-05-052041-11-05031
12616743Streptococcal GlcNAc-lacking glycopolypeptides, cell wall carbohydrates, streptococcus vaccines, and methods for making and using them🖼🧊📄§2026-05-052043-08-16031
12616746Infectious disease antigens and vaccines🖼🧊📄§2026-05-052042-10-03031
12616744Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof🖼🧊📄§2026-05-052043-12-06031
12616753HSP70 inhibitors and methods of using same🖼🧊📄§2026-05-052041-03-30031
12616752Pharmaceutical compositions comprising meloxicam🖼🧊📄§2026-05-052045-06-05031
12616754Composition for delivery of a bioactive agent and method of manufacture and use thereof🖼🧊📄§2026-05-052040-07-14031
12616807Medical counter measures including dry powder formulations and associated methods🖼🧊📄§2026-05-052044-05-20031
12618048Dual CAR-T cells🖼🧊📄§2026-05-052041-07-30031
12617816Composition and method for in vivo assay of opioid receptors🖼🧊📄§2026-05-052040-11-11031
12616661Composition for type II diabetics and for use in providing sustained energy release over time🖼🧊📄§2026-05-052039-03-07031
12617827Self-assembling peptide🖼🧊📄§2026-05-052041-07-29031
12617903Process for producing a composition comprising a crosslinked hydrogel🖼🧊📄§2026-05-052040-12-08031
12620489Method for determining the risk to develop type 1 diabetes🖼🧊📄§2026-05-052038-06-27031
12617857Chemokine receptor 4 (CXCR4) antagonist antibodies🖼🧊📄§2026-05-052041-04-22031
12616720Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo🖼🧊📄§2026-05-052042-06-10031
12617853Low pH pharmaceutical composition comprising T cell engaging antibody constructs🖼🧊📄§2026-05-052038-02-02031
12618055Hyaluronidase variants with improved stability and pharmaceutical composition comprising the same🖼🧊📄§2026-05-052041-01-25031
12616848Energy augmentation structures, energy emitters or energy collectors containing the same, and their use in solar cells and other energy conversion devices🖼🧊📄§2026-05-052043-12-15031
12616643Method of preparing new biomaterials for dental pulp regeneration and a composition of new biomaterials prepared accordingly🖼🧊📄§2026-05-052043-10-26031
12616645Water soluble shampoo container🖼🧊📄§2026-05-052043-07-13031
12616232Fasting mimicking diet🖼🧊📄§2026-05-052040-09-01031
12616755Antifungal quercetin conjugates, methods of preparation and uses thereof🖼🧊📄§2026-05-052045-10-08031
12616652Lenses for treating ocular diseases and preparation method thereof🖼🧊📄§2026-05-052042-12-29031
12616745Influenza virus backbone🖼🧊📄§2026-05-052040-06-05031
12616733XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions🖼🧊📄§2026-05-052041-02-10031
12616714Enhanced oligonucleotides for modulating FUBP1 expression🖼🧊📄§2026-05-052041-06-25031